AIM Concept Integration
4th Year MBBS
Renal Module
4th Year MBBS
Renal Module
Chronic Kidney Disease, Renal Replacement Therapy and Renal Transplantation
Connect CKD progression, systemic consequences, renal replacement, transplantation, rejection, ethics and pregnancy care into one rapid-revision framework.
1. THE TOPIC IN ONE CONNECTED FLOW
CKD begins with persistent renal damage and progressive loss of functioning nephrons. The remaining nephrons compensate, but continued stress promotes further sclerosis and fibrosis. As GFR falls, renal excretory, regulatory and endocrine functions fail, producing systemic complications that may eventually require dialysis or renal transplantation.
Persistent Renal Injury
Diabetes, hypertension, glomerular or structural disease
→
Nephron Loss
Surviving nephrons hyperfilter
→
Progressive Scarring
Glomerulosclerosis + tubular atrophy + interstitial fibrosis
→
Falling GFR
Reduced filtration and renal reserve
→
Systemic Effects
Uremia, fluid overload, acidosis, hyperkalemia, anemia, bone disorder
→
Renal Replacement
Hemodialysis or peritoneal dialysis when complications become uncontrolled
→
Transplantation
Suitable recipient + donor + compatibility + lifelong graft care
2. KEY CLINICAL CONNECTIONS
CKD Complications → Dialysis Decision
Severe nephron loss
→
inadequate potassium, acid, fluid and toxin removal
→
refractory hyperkalemia, severe acidosis, pulmonary edema, encephalopathy or pericarditis
→
dialysis becomes necessary.
→
inadequate potassium, acid, fluid and toxin removal
→
refractory hyperkalemia, severe acidosis, pulmonary edema, encephalopathy or pericarditis
→
dialysis becomes necessary.
Clinical decision is based on uncontrolled complications, not serum creatinine alone.
Transplantation → Immunity → Graft Survival
Donor antigens
→
recipient cellular or antibody response
→
graft injury
→
immunosuppressive therapy
→
reduced rejection risk.
→
recipient cellular or antibody response
→
graft injury
→
immunosuppressive therapy
→
reduced rejection risk.
Hyperacute rejection
→
pre-existing antibodies and vascular thrombosis;
acute rejection
→
cellular and/or antibody injury;
chronic rejection
→
progressive vascular and interstitial scarring.
→
pre-existing antibodies and vascular thrombosis;
acute rejection
→
cellular and/or antibody injury;
chronic rejection
→
progressive vascular and interstitial scarring.
Transplantation → Ethics and Pregnancy
Living donation
→
informed voluntary consent + donor safety + no commercial exploitation
→
ethical and lawful transplantation.
→
informed voluntary consent + donor safety + no commercial exploitation
→
ethical and lawful transplantation.
Pregnancy with CKD or transplant
→
assess renal function, proteinuria, blood pressure and medicines
→
coordinated renal-obstetric care and pregnancy-compatible therapy.
→
assess renal function, proteinuria, blood pressure and medicines
→
coordinated renal-obstetric care and pregnancy-compatible therapy.
3. AIM HIGH-YIELD INTEGRATION REVIEW
⭐ Persistent nephron loss → hyperfiltration of surviving nephrons → glomerular stress → further sclerosis and falling GFR.
Glomerulosclerosis + tubular atrophy + interstitial fibrosis → irreversible loss of renal parenchyma → chronic functional decline.
Reduced erythropoietin → impaired red-cell production → anemia; phosphate retention + reduced active vitamin D → secondary hyperparathyroidism and bone disease.
⭐ Hyperkalemia, severe acidosis, pulmonary edema, uremic encephalopathy or pericarditis → clinically important indication for dialysis.
Hemodialysis uses an extracorporeal membrane; peritoneal dialysis uses the peritoneum → both remove solutes by diffusion and excess fluid across a semipermeable membrane.
⭐ Pre-existing anti-donor antibodies → hyperacute rejection; therefore donor-recipient compatibility assessment and crossmatching protect the graft before transplantation.
Calcineurin inhibitors suppress T-cell activation → reduce rejection, but their nephrotoxicity means graft dysfunction must not automatically be labeled as rejection.
⭐ CKD or renal transplantation in pregnancy → assess renal stability and medication safety; mycophenolate is teratogenic, while appropriate immunosuppression should be maintained to protect the graft.